Keros Therapeutics (KROS) Tops Q3 EPS by 87c
Tweet
Share
E-mailGet Alerts KROS Hot Sheet
Join SI Premium – FREE
Keros Therapeutics (NASDAQ: KROS) reported Q3 EPS of ($0.18), $0.87 better than the analyst estimate of ($1.05). Revenue for the quarter came in at $14.26 million versus the consensus estimate of $6.33 million.
For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Phillips 66, Marathon Merger Talks Collapsed - Semafor
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
